Bruton's tyrosine kinase inhibitors
US-2016376281-A1 · Dec 29, 2016 · US
Pyrimidinyl tyrosine kinase inhibitors
US9944622B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9944622-B2 |
| Application number | US-201615196389-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2016 |
| Priority date | Jun 8, 2012 |
| Publication date | Apr 17, 2018 |
| Grant date | Apr 17, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 10. A method for decreasing the enzymatic activity of Bruton's tyrosine kinase comprising contacting Bruton's tyrosine kinase with an effective amount of a compound of claim 1 or a composition thereof. 11. A method for treating a disorder in a human subject in need of treatment for dysregulation of BCR signaling, the method comprising: administering to the subject an effective amount of a compound of claim 1 or a composition thereof, the compound being a Bruton's tyrosine kinase inhibitor; wherein the disorder is responsive to B-cell depletion. 12. A method for treating a disorder selected from the group consisting of autoimmune disorders, inflammatory disorders, and cancers affiliated with B-cells, the method comprising: administering to a human subject an effective amount of a compound of claim 1 or a composition thereof; wherein the disorder is responsive to B-cell depletion. 13. The method of claim 12 , wherein the disorder is rheumatoid arthritis. 14. The method of claim 12 , wherein the disorder is systemic lupus erythematosus. 15. The method of claim 12 , wherein the disorder is atopic dermatitis. 16. The method of claim 12 , wherein the disorder is leukemia or lymphoma.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9944622B2 cover?
- The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
- Who is the assignee on this patent?
- Biogen Ma Inc, Sunesis Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).